中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 6
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(6): 1358-1365

Clinical features of patients with drug-induced liver injury in Shaanxi Province from 2009 to 2019

DOI: 10.3969/j.issn.1001-5256.2023.06.016

  • Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

Research funding:

2016 Shaanxi Science and Technology Overall Planning and Innovation Project (2016KTCL03-04)

More Information
  • Corresponding author: GUO Xiaoyan, gxiaoyan5999@163.com (ORCID: 0000-0003-0487-1471)
  • Received Date: 2022-09-27
  • Accepted Date: 2022-12-07
  • Published Date: 2023-06-20
    Abstract
  •   Objective  To investigate the clinical features of patients with drug-induced liver injury (DILI).  Methods  A retrospective analysis was performed for the clinical data of 1 376 patients with DILI who were admitted to 20 hospitals in Shaanxi Province, China, from 2009 to 2019 and were diagnosed with RUCAM scale as the diagnostic criteria, and these patients were analyzed in terms of sex, age, underlying diseases, suspected drugs causing DILI, clinical manifestations, laboratory examination, treatment process, and prognosis. The t-test and Wilcoxon test were used for comparison of continuous data between two groups, the chi-square test was used for comparison of categorical data between groups, and the Kruskal-Wallis H rank sum test was used for comparison of ordered polytomous data between groups.  Results  Among the 1 376 patients, there were 577(41.93%) male patients and 799 (58.07%) female patients, with a male/female ratio of 0.72:1. As for different age groups, the 40-60 years group had a higher incidence rate and accounted for 44.77%, and there was a significant difference in sex distribution between different age groups (χ2=20.784, P=0.008). As for the three clinical types, there was no significant difference in incidence rate between men and women (χ2=1.409, P=0.494), and there was a significant difference in the distribution of clinical types between different age groups (χ2=47.025, P < 0.001). The top three drugs causing DILI were traditional Chinese medicine (41.13%), antitubercular agents (11.70%), and antipyretic and analgesic drugs (7.27%). Hepatocellular injury type was the main clinical type and accounted for 65.77% (905 cases). The mean length of hospital stay was 15.31 days, mostly 1-4 weeks which accounted for 91.86%. Among these 1376 patients, 45 (3.27%) were cured and 1 322 (96.08%) were improved, suggesting a good overall prognosis. The patients with different clinical types had significantly different prognoses (H=59.300, P=0.011), and further comparison showed that the patients with hepatocellular injury type and mixed type had a significantly better prognosis than those with cholestasis type (P < 0.05), while there was no significant difference in prognosis between the patients with hepatocellular injury type and those with mixed type (P > 0.05).  Conclusion  There is a high incidence rate of DILI in women and middle-aged and elderly people, and traditional Chinese medicine is the leading cause of DILI. Patients with different clinical types tend to have different prognoses, with a good overall prognosis.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [2]
    HAYASHI PH, BJORNSSON ES. Long-term outcomes after drug-induced liver injury[J]. Curr Hepatol Rep, 2018, 17(3): 292-299. DOI: 10.1007/s11901-018-0411-0.
    [3]
    LO REV 3rd, HAYNES K, FORDE KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model[J]. Clin Gastroenterol Hepatol, 2015, 13(13): 2360-2368. DOI: 10.1016/j.cgh.2015.06.020.
    [4]
    YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241. DOI: 10.1007/s12072-017-9793-2.
    [5]
    DANAN G, BENICHOU C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries[J]. J Clin Epidemiol, 1993, 46(11): 1323-1330. DOI: 10.1016/0895-4356(93)90101-6.
    [6]
    HAYASHI PH, FONTANA RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury[J]. Semin Liver Dis, 2014, 34(2): 134-144. DOI: 10.1055/s-0034-1375955.
    [7]
    CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.1055/s-0034-1375955.
    [8]
    WANG J, SONG YY, LI Y. Case analysis of 104 cases of drug-induced liver injury[J]. Chin J Drug Appl Monit, 2020, 17(1): 37-40, 66. DOI: 10.3969/j.issn.1672-8157.2020.01.010.

    王洁, 宋艳艳, 李颖. 104例药物性肝损伤的病例分析[J]. 中国药物应用与监测, 2020, 17(1): 37-40, 66. DOI: 10.3969/j.issn.1672-8157.2020.01.010.
    [9]
    HE WC, ZHANG KG, ZHAO FH. Clinical characteristics of 290 patients with drug-related liver injury[J]. J Prac Hepatol, 2020, 23(4): 540-543. DOI: 10.3969/j.issn.1672-5069.2020.04.022.

    何文昌, 张克恭, 赵凡惠. 290例药物性肝损伤患者临床特征分析[J]. 实用肝脏病杂志, 2020, 23(4): 540-543. DOI: 10.3969/j.issn.1672-5069.2020.04.022.
    [10]
    BJÖRNSSON ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury[J]. Semin Liver Dis, 2014, 34(2): 115-122. DOI: 10.1055/s-0029-1240002.
    [11]
    RATHI C, PIPALIYA N, PATEL R, et al. Drug induced liver injury at a tertiary hospital in india: etiology, clinical features and predictors of mortality[J]. Ann Hepatol, 2017, 16(3): 442-450. DOI: 10.5604/16652681.1235488.
    [12]
    FONTANA RJ, WATKINS PB, BONKOVSKY HL, et al. DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct[J]. Drug Saf, 2009, 32(1): 55-68. DOI: 10.2165/00002018-200932010-00005.
    [13]
    BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425.e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
    [14]
    LI YF, HAN SJ, GUO YZ. Clinical characteristics analysis of 103 cases of drug-related liver injury[J]. Chin Hepatol, 2019, 24(4): 386-389. DOI: 10.3969/j.issn.1008-1704.2019.04.015.

    李亚飞, 韩少静, 郭永泽. 103例药物性肝损伤的临床特征分析[J]. 肝脏, 2019, 24(4): 386-389. DOI: 10.3969/j.issn.1008-1704.2019.04.015.
    [15]
    XU QL, HE LL, LI C. Clinical study of 516 cases of drug-induced liver injury[J]. Baiqiuen Med J, 2019, 17(3): 223-225. DOI: 10.16485/j.issn.2095-7858.2019.03.006.

    徐庆玲, 何兰兰, 李纯. 516例药物性肝损伤的临床研究[J]. 白求恩医学杂志, 2019, 17(3): 223-225. DOI: 10.16485/j.issn.2095-7858.2019.03.006.
    [16]
    ZHANG XY, CHEN HQ, BAI C. Clinical characteristics of drug-related liver injury and its prognostic assessment[J]. Contemp Med, 2019, 25(7): 137-139. DOI: 10.3969/j.issn.1009-4393.2019.07.055.

    张旭艳, 陈慧群, 白成. 药物性肝损伤的临床特点及其预后评估[J]. 当代医学, 2019, 25(7): 137-139. DOI: 10.3969/j.issn.1009-4393.2019.07.055.
    [17]
    ZHANG X. Clinical comparison analysis of drug-induced liver injury by Chinese and Western drugs[J]. China J Phar Economics, 2016, 11(10): 65-67. DOI: 10.12010/j.issn.1673-5846.2016.10.026.

    张项. 中药与西药所致药物性肝损伤的临床对比分析[J]. 中国药物经济学, 2016, 11(10): 65-67. DOI: 10.12010/j.issn.1673-5846.2016.10.026.
    [18]
    LI XY, TANG JT. Epidemiology of drug-related liver injury[J]. J Clin Hepatol, 2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001.5256.2021.11.002.

    李晓芸, 唐洁婷. 药物性肝损伤的流行病学[J]. 临床肝胆病杂志, 2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001-5256.2021.11.002.
    [19]
    WANG JH, GUO HD, KONG JJ. Clinical characteristics of patients with drug-induced liver injury caused by anti-tuberculosis drugs and analysis of their risk factors[J]. J Prac Hepatol, 2020, 23(1): 58-61. DOI: 10.3969/j.issn.1672-5069.2020.01.017.

    王建辉, 郭红丹, 孔晶晶. 抗结核药物致药物性肝损伤患者临床特点及其危险因素分析[J]. 实用肝脏病杂志, 2020, 23(1): 58-61. DOI: 10.3969/j.issn.1672-5069.2020.01.017.
    [20]
    LEE WM. Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?[J]. J Hepatol, 2017, 67(6): 1324-1331. DOI: 10.1016/j.jhep.2017.07.005.
    [21]
    LAMMERT C, EINARSSON S, SAHA C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals[J]. Hepatology, 2008, 47(6): 2003-2009. DOI: 10.1002/hep.22272.
    [22]
    LI Z, SU H, LENG J. Analysis of the status of drug-related liver damage at home and abroad[J]. Mil Med J Southeast China, 2007, 169(6): 476-480. DOI: 10.3969/j.issn.1672-271X.2007.06.046.

    李治, 苏华, 冷静. 国内外药物性肝损害状况分析[J]. 东南国防医药, 2007, 169(6): 476-480. DOI: 10.3969/j.issn.1672-271X.2007.06.046.
    [23]
    HU Q, LIU W, SHAO H. Research progress in pharmacological treatment of drug-related liver injury[J]. Chin J Clin Pharmacol Ther, 2016, 21(2): 231-236. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL201602026.htm

    胡琴, 刘维, 邵宏. 药物性肝损伤的药物治疗研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 231-236. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZL201602026.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (965) PDF downloads(130) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return